About Basilea Pharmaceutica

Basilea Pharmaceutica AG, an independent biopharmaceutical company, engages in the development of anti-bacterial and anti-fungal agents to fight drug resistance, as well as on dermatology drugs. Through its subsidiary Jiangsu Innovative New Drug Research Center Co. Ltd. (JI Pharma), the company engages in providing complementary services, primarily in the field of chemical synthesis research and development, in connection with Basilea’s research and development compounds. In 2004, the company started phase III development for its compounds BAL5788 and BAL4079. Furthermore, BAL8557 entered into phase II of clinical development. Products BAL5788 Ceftobiprole (BAL5788), anti-MRSA cephalosporins with good activity against methicillin-resistant Staphylococcus aureus (MRSA), has entered Phase III clinical development. BAL8557 BAL8557 is an azole prodrug that can be given orally and intravenously with the potential to treat mucocutaneous and invasive fungal infections, and fungal infections of the nail. Phase II clinical development of BAL8557 has started in December 2004. BAL4079 BAL4079 is an oral once-daily retinoid for uses as a first line treatment for patients with chronic hand dermatitis refractory to topical steroids. Preclinical Development: The company’s preclinical development portfolio includes the first clinical candidate from the macrolide project to be advanced into preclinical development; and â-lactam program. Recent developments: In February 2005, the company entered into a royalty-bearing licensing, development, and co-promotion agreement with Cilag AG International, Zug, Switzerland (Licensee), a subsidiary of Johnson & Johnson, under which the company grants the Licensee an exclusive worldwide license to develop and commercialize the company’s antibiotic compound ceftobiprole (BAL5788). Under this agreement, the company retains the option to co-promote ceftobiprole in major market countries. History Basilea Pharmaceutica AG was founded in 2000.